AKT1 and neoplasm: These findings indicate that CVM-A inhibits the critical components of the PI3K/Akt/mTOR pathway under tumor microenvironment mimicking condition of nutrition deprivation, reinforcing its potential as a candidate for pancreatic cancer drug development.